{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:09:12Z","timestamp":1774534152441,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T\u2010cell acute lymphoblastic leukemia (T\u2010ALL) and T\u2010cell lymphoblastic lymphoma (T\u2010LBL) are neoplasms that originate from T\u2010cell precursors. Outcomes in adult patients with T\u2010ALL\/LBL remain unsatisfactory; early relapse following intensive induction chemotherapy is a concern, and patients with relapsed or refractory disease have a poor prognosis. Romidepsin is a potent, class 1 selective histone deacetylase inhibitor approved for the treatment of patients with peripheral T\u2010cell lymphoma who have had \u22651 prior therapy and patients with cutaneous T\u2010cell lymphoma who have had \u22651 prior systemic therapy. Here, we report the case of an adult patient with T\u2010ALL refractory to induction hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper\u2010CVAD). Treatment with romidepsin was initiated, and romidepsin in combination with hyper\u2010CVAD resulted in complete remission, with mild tumor lysis syndrome as the only detectable additional toxicity. The patient eventually underwent allogeneic stem cell transplant while in first complete remission. Prior studies have shown that romidepsin is capable of inducing durable responses with manageable toxicities in patients with mature T\u2010cell lymphomas. This case study describes the successful use of romidepsin in combination with hyper\u2010CVAD in an adult patient with refractory T\u2010ALL and highlights the activity of romidepsin in the T\u2010cell lineage. The potential of romidepsin\u2010containing regimens in patients with T\u2010ALL\/LBL deserves further study.<\/jats:p>","DOI":"10.1002\/hon.2421","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T04:16:44Z","timestamp":1496204204000},"page":"340-343","source":"Crossref","is-referenced-by-count":10,"title":["Complete remission with romidepsin in a patient with <scp>T<\/scp>\u2010cell acute lymphoblastic leukemia refractory to induction hyper\u2010<scp>CVAD<\/scp>"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-2699","authenticated-orcid":false,"given":"Mark W.","family":"Brunvand","sequence":"first","affiliation":[{"name":"Colorado Blood Cancer Institute  Denver CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Carson","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute  Denver CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.s.015"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20550"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404156"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.12.003"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551895"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231217"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199380"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-661702"},{"key":"e_1_2_6_14_1","unstructured":"ISTODAX(romidepsin) [package insert].2016."},{"key":"e_1_2_6_15_1","unstructured":"NCCN clinical practice Guidelines in Oncology: acute lymphoblastic leukemia. V.2.2016."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.312"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2020"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.03.008"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Valdez BC","year":"2015","journal-title":"Blood Cancer J"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13566"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1282.1282","article-title":"Targeting epigenetic operations with HDAC inhibitor and Hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant T\u2010cell lymphoma (TCL): A translational focus on doublet development","volume":"126","author":"O'Connor OA","year":"2015","journal-title":"Blood"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:56:44Z","timestamp":1695553004000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2421"],"URL":"https:\/\/doi.org\/10.1002\/hon.2421","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}